Khang & Khang LLP (the “Firm”) announces that it is investigating claims against AngioDynamics, Inc. (“AngioDynamics” or the “Company”) (Nasdaq: ANGO) concerning possible violations of federal securities laws.

If you purchased shares of AngioDynamics and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

The investigation concerns whether AngioDynamics and certain of its directors and/or officers violated federal securities laws. On July 17, 2017, the Company announced that its auditor discovered that a material weakness existed in its internal control over financial reporting as of May 31, 2016 because AngioDynamics did not design and maintain effective internal controls over the accounting for the annual goodwill impairment test. The Company lacked effective controls to review in sufficient detail the cash flow projections and significant valuation model assumptions used in the goodwill impairment test as of December 31, 2015. When this news was announced, shares of AngioDynamics fell in value.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.